How This Evidence Evolved
Watch-and-Wait in Rectal Cancer
Organ Preservation Following Complete Clinical Response to Neoadjuvant Therapy
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Local regrowth mostly within 2 years and in bowel wall; unsalvageable disease rare
3-year DFS: INCT-CRT 76% vs CRT-CNCT 76%; TME-free survival 41% vs 53%.
Follow-up studies, subgroup analyses, and real-world validation
Integration into clinical practice guidelines and recommendations
Current standard of care and ongoing research directions
Landmark Trials in This Story
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
5-year survival, observation vs resection: OS 100% vs 88%; DFS 92% vs 83%.
Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study
Local regrowth mostly within 2 years and in bowel wall; unsalvageable disease rare
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy
3-year DFS: INCT-CRT 76% vs CRT-CNCT 76%; TME-free survival 41% vs 53%.
Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.
5-year DFS: INCT-CRT 71% vs CRT-CNCT 69% (P=.68); TME-free survival 39% vs 54% (P=.012).
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.